Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)
07 sept. 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
Established animal model of AKI showed a statistically significant reduction of a key biomarker of kidney injury when treated with UNI-494 AKI remains a serious unmet medical need with no FDA...
Unicycive Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022
24 août 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Second Quarter Financial Results and Provides Business Update
15 août 2022 18h03 HE
|
Unicycive Therapeutics, Inc.
On track to file New Drug Application for Renazorb, the first proprietary nanoparticle-based phosphate binder for Chronic Kidney Disease (CKD) patients, by end of 2023 Signed first global...
Unicycive Reports Key Findings from Independent Renal Dietitian Survey
26 juil. 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
Hyperphosphatemia ranked as area of greatest unmet need Highlights most appealing benefits of Renazorb as efficacy/potency and lower pill burden Confirms patient preference for pills that are...
Unicycive Reports Key Findings from Market Research with Nephrologists
20 juil. 2022 07h12 HE
|
Unicycive Therapeutics, Inc.
Renazorb product profile rated as best-in-class phosphate binder Nephrologists report high prescribing intent for Renazorb pending FDA approval LOS ALTOS, Calif., July 20, 2022 (GLOBE...
Unicycive Announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets
18 juil. 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
Expands and accelerates Renazorb opportunity in important markets for patients with hyperphosphatemia through local partner with deep domain expertise Agreement includes upfront payment, royalties...
Unicycive to Present at JMP Securities Life Sciences Conference
06 juin 2022 08h00 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia
02 juin 2022 08h00 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease today...
Unicycive Announces First Quarter Financial Results and Provides Business Update
12 mai 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in second quarter 2022 Plans to initiate Phase 1 study for UNI-494 in second half of...